www.fgks.org   »   [go: up one dir, main page]

Latest Updates in Multispecialty

  • FDA Approves First Test to Predict AKI in Critically Ill Patients The FDA has approved the first laboratory test to evaluate the risk of developing moderate to severe acute kidney injury in hospitalized, critically ill patients.
  • ASCO Issues Guideline on Treatment of HER-2 Advanced Breast Cancer The American Society of Clinical Oncology has published a clinical practice guideline on the use of chemotherapy and targeted therapy for women with human epidermal growth factor 2 (HER2)-negative (or unknown) advanced breast cancer
  • New International Standards Developed for Fetal Growth and Newborn Size Researchers have developed the first set of international standards for fetuses and newborns as well as for preterm infants in the postnatal growth period. These standards complement the World Health Organization’s international growth standards for children from birth up to the age of 5
  • New Guidelines for Managing Hip Fracture in the Elderly The American Academy of Orthopaedic Surgeons has released new, evidence-based guidelines for the management of hip fractures in patients over the age of 65
  • Top 10 Trends in Medicine, August 2014 Clinicians are searching for information on these drugs and diseases. View these topics to be up to speed on the latest clinical knowledge and to stay abreast of emerging clinical trends. The top 10 articles for Medscape Trends in Medicine are updated monthly based on search referral data
 

Drug Updates

  • dulaglutide (Trulicity) FDA approves new once-weekly GLP-1 agonist for type 2 diabetes mellitus
  • naloxegol (Movantik) FDA approves first peripherally-acting mu-opioid receptor antagonist (PAMORA) for opioid-induced constipation in adults with chronic noncancer pain
  • ferric citrate FDA approves oral phosphate binder approved for dialysis patients with hyperphosphatemia
  • Factor IX, recombinant (Rixubis) New indication approved for children with hemophilia B
  • immune globulin SC (HyQvia) New SC brand approved with longer dosing interval for primary immunodeficiency syndromes
  • bupropion/naltrexone (Contrave) FDA okays an antidepressant/opioid antagonist drug combination for the treatment of obesity.
  • enzalutamide (Xtandi) FDA expands indication of enzalutamide (Xtandi) for use in metastatic castration-resistant prostate cancer patients who have not received chemotherapy
  • pembrolizumab (Keytruda) FDA okays the first immunomodulator, that acts as a program death (PD) inhibitor, for the treatment of advanced or unresectable melanoma that is no longer responding to other drugs
  • lacosamide (Vimpat) New indication for use as monotherapy in adults with partial seizures
  • taliglucerase alfa (Elelyso) Indication expanded to include children aged 4 years or older
 
 

Advisory Board

  • David Chelmow, MD, Leo J Dunn Distinguished Professor of Obstetrics and Gynecology, Virginia Commonwealth University Medical Center
  • John Geibel, MD, DSc, MA, Professor of Surgery, Yale University School of Medicine
  • Lars Grimm, MD, MHS, Duke University Medical Center
  • Jules E Harris, MD, Clinical Professor of Medicine, University of Arizona College of Medicine at Tucson
  • David J Maron, MD, FACC, FAHA, Professor of Medicine and Emergency Medicine, Vanderbilt University School of Medicine
  • Arlen D Meyers, MD, MBA, Professor of Otolaryngology and Dentistry, University of Colorado School of Medicine
  • Thomas M Wheeler, MD, Harlan J Spjut Professor of Pathology, Professor of Urology, Baylor College of Medicine
All material on this website is protected by copyright, Copyright © 1994-2014 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.